Cartesian Therapeutics, Inc.
RNAC
$6.65
-$0.06-0.89%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 51.68% | -72.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 51.68% | -72.91% | |||
| Cost of Revenue | 607.02% | 41.96% | |||
| Gross Profit | -716.47% | -764.00% | |||
| SG&A Expenses | 6.57% | -12.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.67% | -3.83% | |||
| Operating Income | 3.42% | 0.36% | |||
| Income Before Tax | -326.00% | 189.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -326.00% | 189.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -326.00% | 189.70% | |||
| EBIT | 3.42% | 0.36% | |||
| EBITDA | 3.59% | -2.36% | |||
| EPS Basic | -370.57% | 187.65% | |||
| Normalized Basic EPS | 2.21% | -7.18% | |||
| EPS Diluted | -376.14% | 185.88% | |||
| Normalized Diluted EPS | 0.46% | -5.30% | |||
| Average Basic Shares Outstanding | 0.09% | 0.30% | |||
| Average Diluted Shares Outstanding | -1.68% | 2.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||